Literature DB >> 6404503

Apomorphine-induced changes in local cerebral blood flow in normal rats and after lesions of the dopaminergic nigrostriatal bundle.

M Ingvar, O Lindvall, U Stenevi.   

Abstract

Systemic administration of the dopamine (DA) receptor agonist apomorphine leads to a general increase in cerebral blood flow (CBF) as determined by the autoradiographic iodoantipyrine technique. The magnitude of the increase varies between different regions but shows no obvious relation to the density of either DA terminals or receptors. The circulatory response is much more prominent in the lateral than in the medial caudate-putamen. Apomorphine seems to increase CBF both via a change in metabolic rate and via stimulation of dilatory vascular receptors. In animals with unilateral 6-hydroxydopamine lesions of the ascending DA pathways apomorphine induces an augmented CBF response in some denervated structures, notably caudate-putamen and globus pallidus. It is concluded that this is partly due to stimulation of denervated supersensitive vascular receptors, suggesting a direct dopaminergic control of the blood vessels in these areas.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404503     DOI: 10.1016/0006-8993(83)91016-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Changes in brain functional activation during resting and locomotor states after unilateral nigrostriatal damage in rats.

Authors:  J Yang; T R Sadler; T K Givrad; J-M I Maarek; D P Holschneider
Journal:  Neuroimage       Date:  2007-03-23       Impact factor: 6.556

2.  Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.

Authors:  U Sabatini; O Rascol; P Celsis; G Houin; A Rascol; J P Marc-Vergnes; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

3.  Modulation of Postnatal Neurogenesis by Perinatal Asphyxia: Effect of D1 and D2 Dopamine Receptor Agonists.

Authors:  A Tapia-Bustos; R Perez-Lobos; V Vío; C Lespay-Rebolledo; E Palacios; A Chiti-Morales; D Bustamante; M Herrera-Marschitz; P Morales
Journal:  Neurotox Res       Date:  2016-09-16       Impact factor: 3.911

4.  Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations.

Authors:  E Melamed; M Globus; B Mildworf
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

5.  Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.

Authors:  Shigeki Hirano; Kotaro Asanuma; Yilong Ma; Chengke Tang; Andrew Feigin; Vijay Dhawan; Maren Carbon; David Eidelberg
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

6.  PET measurement of dopamine D2 receptor-mediated changes in striatopallidal function.

Authors:  K J Black; M H Gado; J S Perlmutter
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.